Press Releases

SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region BETHESDA, Md., August 6, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and... Read More

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated BETHESDA, Md., July 8, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company’s Chief Technical Officer, Dr. Marnix Bosch, presented updated... Read More

BETHESDA, Md., July 2, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company’s Chief Technical Officer, will be making a scientific presentation entitled “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses” at the 2026 Annual... Read More

BETHESDA, MD, April 30, 2026 — Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the appointment of Annalisa Jenkins, M.B.B.S., F.R.C.P., as a Strategic Adviser.Dr. Jenkins brings over 25 years of biopharma leadership, spanning global R&D executive roles at major pharmaceutical... Read More

BETHESDA, MD, April 21, 2026 — Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is establishing its own dedicated clinic for leukapheresis procedures at The London Welbeck Hospital. The Company is doing so in order to proactively address potential constraints in available leukapheresis... Read More